- Investing.com
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.9x | −0.6x | |
PEG Ratio | 0.00 | 0.08 | 0.00 | |
Price/Book | 0.0x | 5.2x | 2.6x | |
Price / LTM Sales | 0.0x | 4.9x | 3.3x | |
Upside (Analyst Target) | 0.0% | 38.6% | 44.3% | |
Fair Value Upside | Unlock | 10.0% | 6.1% | Unlock |